Insider Selling: Bioventus Inc. (NYSE:BVS) SVP Sells 4,380 Shares of Stock

Bioventus Inc. (NYSE:BVS) SVP Anthony D’adamio sold 4,380 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $10.19, for a total transaction of $44,632.20. Following the sale, the senior vice president now owns 118,178 shares of the company’s stock, valued at approximately $1,204,233.82. This represents a 3.57 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Bioventus Stock Up 0.6 %

Shares of NYSE:BVS opened at $10.01 on Friday. The company has a market capitalization of $812.31 million, a price-to-earnings ratio of -16.41 and a beta of 0.85. The company has a 50 day moving average of $10.32 and a two-hundred day moving average of $10.86. Bioventus Inc. has a 52-week low of $3.90 and a 52-week high of $14.38. The company has a quick ratio of 0.99, a current ratio of 1.41 and a debt-to-equity ratio of 1.85.

Wall Street Analysts Forecast Growth

BVS has been the topic of several recent research reports. Canaccord Genuity Group lifted their target price on shares of Bioventus from $12.00 to $15.00 and gave the company a “buy” rating in a report on Wednesday, November 6th. JPMorgan Chase & Co. upgraded Bioventus from an “underweight” rating to a “neutral” rating and boosted their price objective for the stock from $12.00 to $13.00 in a research note on Tuesday, December 17th.

Institutional Investors Weigh In On Bioventus

Large investors have recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. lifted its holdings in Bioventus by 38.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 390,162 shares of the company’s stock worth $4,662,000 after buying an additional 109,359 shares in the last quarter. Segall Bryant & Hamill LLC acquired a new stake in shares of Bioventus during the third quarter valued at about $4,515,000. Point72 Asset Management L.P. purchased a new stake in shares of Bioventus during the third quarter worth about $788,000. JPMorgan Chase & Co. lifted its stake in shares of Bioventus by 228.3% in the third quarter. JPMorgan Chase & Co. now owns 253,740 shares of the company’s stock worth $3,032,000 after acquiring an additional 176,442 shares in the last quarter. Finally, State Street Corp boosted its holdings in Bioventus by 38.8% in the third quarter. State Street Corp now owns 676,501 shares of the company’s stock valued at $8,084,000 after purchasing an additional 189,216 shares during the last quarter. 62.94% of the stock is owned by institutional investors and hedge funds.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.